Quick Answer
PALVELLA THERAPEUTICS, INC. reported Earnings Per Share Diluted of $3.71 (loss) per share for the year ending 2025.
- PALVELLA THERAPEUTICS, INC. showed an increase of +52.6% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from PALVELLA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.09 (loss) per share | Q3 2020: $0.26 (loss) per share | Q1 2021: $0.07 (loss) per share | Q2 2021: $0.25 (loss) per share | Q3 2021: $0.24 (loss) per share | Q1 2022: $0.07 (loss) per share | Q2 2022: $0.14 (loss) per share | Q2 2023: $3.62 per share | Q3 2023: $8.70 (loss) per share | Q1 2024: $1.54 (loss) per share | Q2 2024: $2.47 (loss) per share | Q3 2024: $3.94 (loss) per share | Q1 2025: $0.74 (loss) per share | Q2 2025: $0.86 (loss) per share | Q3 2025: $1.03 (loss) per share.
- Over the full 5 years of available data (2020 to 2025), PALVELLA THERAPEUTICS, INC.'s Earnings Per Share Diluted has declined by 445.6%.
- Historical annual values: Fiscal year 2025: $3.71 (loss) per share | Fiscal year 2024: $7.83 (loss) per share | Fiscal year 2023: $2.17 per share | Fiscal year 2021: $0.71 (loss) per share | Fiscal year 2020: $0.68 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: